3.Efficacy and safety of a novel nano-porous polymer-free sirolimus-eluting stent in pigs.
Ming CHEN ; Bo ZHENG ; Zheng WU ; Hong-Yu PENG ; Xin-Gang WANG ; Bin ZHANG ; Yong HUO
Chinese Medical Journal 2013;126(24):4731-4735
BACKGROUNDDrug-eluting stents represent a major advance in interventional cardiology. However, the current drug-eluting stents have significant limitations. One of the major problems is very late stent thrombosis, which is likely caused by inflammation and a hypersensitivity reaction related to a polymer on the stent. A polymer-free sirolimus-eluting stent with a unique nano-porous surface has been developed. This study aimed to evaluate this novel polymer-free sirolimus-eluting stent for its efficacy and safety in a pig model.
METHODSStents were directly coated with sirolimus (a drug concentration of 2.2 µg/mm(2) on the stent surface). The polymer-free sirolimus-eluting stents (PFSES) were compared to standard polymer-coated sirolimus-eluting stents (PCSES) and bare-metal stents (BMS) in 18 pigs.
RESULTSAt one month the degree of neointimal hyperplasia was similar between the two sirolimus-eluting stent groups and was significantly less compared to BMS ((1.93 ± 0.51) mm(2), (1.57 ± 0.69) mm(2) vs. (4.45 ± 1.05) mm(2), P < 0.05) At three months, PFSES maintained the low level of neointima ((2.41 ± 0.99) mm(2) vs. (4.32 ± 1.16) mm(2), P < 0.05), whereas PCSES had developed significant neointimal proliferation similar to BMS. The inflammation level was significantly higher in PCSES when compared with BMS three months post-implantation (2.50 ± 0.55 vs. 0.83 ± 0.75, P < 0.05) whereas PFSES showed a low level of inflammation comparable to PCSES (1.33 ± 0.52 vs. 2.50 ± 0.55, P < 0.05).
CONCLUSIONThe PFSES is effective and safe, and appears to be superior to standard PCSEs.
Animals ; Drug-Eluting Stents ; adverse effects ; Neointima ; prevention & control ; Polymers ; chemistry ; Sirolimus ; therapeutic use ; Swine
6.Safety and efficacy of polymer-free paclitaxel-eluting microporous stent in real-world practice: 1-year follow-up of the SERY-I registry.
Rui-Yan ZHANG ; Qi ZHANG ; Jin-Zhou ZHU ; Liang-Long CHEN ; Chen-Yun ZHANG ; Xu-Chen ZHOU ; Yong YUAN ; Zhi-Xiong ZHONG ; Lang LI ; Jian QIU ; Wei WANG ; Xi-Ming CHEN ; Zhi-Jian YANG ; Jin-Chuan YAN ; Shao-Liang CHEN ; Yu-Qing HOU ; Yan-Qing WU ; Hai-Ming LUO ; Jian-Ping QIU ; Li ZHU ; Yan WANG ; Guo-Sheng FU ; Jian-An WANG ; Kang-Hua MA ; Yue-Hui YIN ; Dai-Fu ZHANG ; Xue-Song HU ; Guo-Ying ZHU ; Wei-Feng SHEN ; null
Chinese Medical Journal 2011;124(21):3521-3526